Consent Details [#IABV2SETTINGS#] About Privacy settings This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more…

Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Allow selection” or "Allow all", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings
. For more information, please see our Cookie Policy
.
[#GPC_BANNER_ICON#]
[#GPC_TOAST_TEXT#]
Consent Selection
Necessary
Preferences
Statistics
Marketing
Show details
Details
-
Necessary 10
Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
-
Cookiebot
1
Learn more about this provider
CookieConsentStores the user's cookie consent state for the current domain
Maximum Storage Duration: 1 yearType: HTTP Cookie
-
Google
2
Learn more about this provider
Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness. The provider may use the IP Addresses for ads measurement and ads personalization.
rc::aThis cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.
Maximum Storage Duration: PersistentType: HTML Local Storage
rc::cThis cookie is used to distinguish between humans and bots.
Maximum Storage Duration: SessionType: HTML Local Storage
-
LinkedIn
2
Learn more about this provider
bcookieUsed in order to detect spam and improve the website's security.
Maximum Storage Duration: 1 yearType: HTTP Cookie
li_gcStores the user's cookie consent state for the current domain
Maximum Storage Duration: 180 daysType: HTTP Cookie
-
linkedin.com
t.co
3
**__cf_bm [x3]**This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.
Maximum Storage Duration: 1 dayType: HTTP Cookie
-
microport.com
2
CraftCookieTestRegisters whether the user is logged in. This allows the website owner to make parts of the website inaccessible, based on the user's log-in status.
Maximum Storage Duration: SessionType: HTTP Cookie
htmx-current-path-for-historyPreserves the visitor's session state across page requests.
Maximum Storage Duration: SessionType: HTML Local Storage
-
Preferences 1
Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
-
LinkedIn
1
Learn more about this provider
lidcRegisters which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
Maximum Storage Duration: 1 dayType: HTTP Cookie
-
Statistics 1
Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
-
Twitter Inc.
1
Learn more about this provider
personalization_idThis cookie is set by Twitter - The cookie allows the visitor to share content from the website onto their Twitter profile.
Maximum Storage Duration: 400 daysType: HTTP Cookie
-
Marketing 21
Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
-
Google
2
Learn more about this provider
Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness. The provider may use the IP Addresses for ads measurement and ads personalization.
_gaUsed to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
Maximum Storage Duration: 2 yearsType: HTTP Cookie
**_ga_#**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
Maximum Storage Duration: 2 yearsType: HTTP Cookie
-
Twitter Inc.
8
Learn more about this provider
**1/i/adsct [x2]**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
Maximum Storage Duration: SessionType: Pixel Tracker
**i/adsct [x2]**The cookie is used by Twitter.com in order to determine the number of visitors accessing the website through Twitter advertisement content.
Maximum Storage Duration: SessionType: Pixel Tracker
muc_adsCollects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
Maximum Storage Duration: 400 daysType: HTTP Cookie
guest_idCollects data related to the user's visits to the website, such as the number of visits, average time spent on the website and which pages have been loaded, with the purpose of personalising and improving the Twitter service.
Maximum Storage Duration: 400 daysType: HTTP Cookie
guest_id_adsCollects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
Maximum Storage Duration: 400 daysType: HTTP Cookie
guest_id_marketingCollects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
Maximum Storage Duration: 400 daysType: HTTP Cookie
-
YouTube
11
Learn more about this provider
LAST_RESULT_ENTRY_KEYUsed to track user’s interaction with embedded content.
Maximum Storage Duration: SessionType: HTTP Cookie
TESTCOOKIESENABLEDUsed to track user’s interaction with embedded content.
Maximum Storage Duration: 1 dayType: HTTP Cookie
yt-icons-last-purgedNecessary for the implementation and functionality of YouTube video-content on the website.
Maximum Storage Duration: PersistentType: HTML Local Storage
ytidb::LAST_RESULT_ENTRY_KEYUsed to track user’s interaction with embedded content.
Maximum Storage Duration: PersistentType: HTML Local Storage
YtIdbMeta#databasesUsed to track user’s interaction with embedded content.
Maximum Storage Duration: PersistentType: IndexedDB
__Secure-BUCKETPending
Maximum Storage Duration: 180 daysType: HTTP Cookie
__Secure-ROLLOUT_TOKENUsed to track user’s interaction with embedded content.
Maximum Storage Duration: 180 daysType: HTTP Cookie
__Secure-YECStores the user's video player preferences using embedded YouTube video
Maximum Storage Duration: SessionType: HTTP Cookie
__Secure-YNIDUsed to track user’s interaction with embedded content.
Maximum Storage Duration: 180 daysType: HTTP Cookie
VISITOR_INFO1_LIVETries to estimate the users' bandwidth on pages with integrated YouTube videos.
Maximum Storage Duration: 180 daysType: HTTP Cookie
YSCRegisters a unique ID to keep statistics of what videos from YouTube the user has seen.
Maximum Storage Duration: SessionType: HTTP Cookie
-
Unclassified 4
Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
-
microport.com
2
MICROPORT_CSRF_TOKENPending
Maximum Storage Duration: SessionType: HTTP Cookie
MicroportSessionIdPending
Maximum Storage Duration: SessionType: HTTP Cookie
-
static.ads-twitter.com
2
_twpidPending
Maximum Storage Duration: SessionType: HTTP Cookie
_twsidPending
Maximum Storage Duration: SessionType: HTTP Cookie
Cross-domain consent[#BULK_CONSENT_DOMAINS_COUNT#]
[#BULK_CONSENT_TITLE#]
List of domains your consent applies to: [#BULK_CONSENT_DOMAINS#]
Cookie declaration last updated on 10/12/26 by Cookiebot
[#IABV2_TITLE#]
[#IABV2_BODY_INTRO#]
[#IABV2_BODY_LEGITIMATE_INTEREST_INTRO#]
[#IABV2_BODY_PREFERENCE_INTRO#]
[#IABV2_LABEL_PURPOSES#]
[#IABV2_BODY_PURPOSES_INTRO#]
[#IABV2_BODY_PURPOSES#]
[#IABV2_LABEL_FEATURES#]
[#IABV2_BODY_FEATURES_INTRO#]
[#IABV2_BODY_FEATURES#]
[#IABV2_LABEL_PARTNERS#]
[#IABV2_BODY_PARTNERS_INTRO#]
[#IABV2_BODY_PARTNERS#]
About
Cookies are small text files that can be used by websites to make a user's experience more efficient.
The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.
This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
You can at any time change or withdraw your consent from the Cookie Declaration on our website.
Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.
Please state your consent ID and date when you contact us regarding your consent.
Do not sell or share my personal information
Deny Allow selection Customize
Allow all

News
MicroPort CardioFlow Announces First Commercial Implantations of AnchorMan® Left Atrial Appendage Closure System in Portugal
16 Sep 2026

Porto, Portugal - September 16, 2026 — MicroPort CardioFlow announced the first two commercial implantations of its AnchorMan® Left Atrial Appendage Closure System in Portugal, marking the system’s entry into its fifth European country.
Left atrial appendage closure (LAAC) is a device-based treatment strategy for stroke prevention in selected patients with atrial fibrillation.1
The procedures were performed at Hospital de Santo António in Porto, part of Unidade Local de Saúde de Santo António (ULS Santo António). They were led by Dr. João António Brum da Silveira, former president of the Portuguese Association of Interventional Cardiology (APIC), alongside his clinical team.
Post-procedural assessments confirmed appropriate device positioning in both cases, with no residual shunts or clinical complications reported at the time of assessment.
“Our experience using the AnchorMan® system has been very positive,” said Dr. João António Brum da Silveira. “Its semi-closed structural design balances strong anchoring force and safety, the delivery system operates smoothly, and the release mechanism is clear and controllable, which gives operators greater confidence. I look forward to applying this innovative device to more patients in Portugal moving forward."
The commercial introduction of AnchorMan® in Portugal further expands the system’s presence in Europe as MicroPort CardioFlow continues to develop its structural heart portfolio internationally.
About MicroPort CardioFlow
MicroPort CardioFlow Medtech Corporation (HKEX: 02160.HK, an associated company of MicroPort Scientific Corporation; HKEX: 00853) develops innovative technologies for structural heart disease and cardiac rhythm management. With roots in the development of therapies for structural heart disease, the company holds a leading position in China's TAVI market and has built one of the broadest portfolios in the segment.
CardioFlow now combines its structural heart business with MicroPort CRM’s more than 60 years of rhythm management expertise, including 12 core development programs and a global portfolio of over 40 marketed products across pacemakers and ICDs. Together these form an integrated platform spanning structural heart intervention and cardiac rhythm management with a unique synergy to address heart failure.
By providing physicians and patients with innovative, full-cycle cardiac health management, the company is dedicated to building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.
More information is available at: https://cf.microport.com/
Regulatory Disclaimer
AnchorMan® has been approved by the National Medical Products Administration (NMPA) in China, is CE marked in the European Union, and is approved in Argentina and Colombia. It is currently commercially available in China, in selected European countries including Portugal and in the Latin American countries listed above.
Regulatory status, intended use/indications and availability vary by country or region, and the product may not be approved or available in your country. AnchorMan® is not cleared or approved by the U.S. FDA and is not available for sale in the United States. This information is not intended to promote the use of the product where it is not authorized. HCPs should refer to applicable local regulatory requirements and to the applicable Instructions for Use. Please contact your regional representative for information on local availability.
Information current as of November 3, 2026.
Reference
- Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36):3314–3414.
MicroPort Forward-Looking Statements
For purposes of this statement, "MicroPort" refers to MicroPort Scientific Corporation (HKEX: 00853) and, where the context requires, one or more of its direct and indirect subsidiaries, affiliates, and other entities under its control, including the business units and operations referenced in this press release. Statements in this press release concerning associated companies, joint ventures or third-party partners are based on information available to MicroPort and should not be interpreted as statements made by, or on behalf of, those entities.
This press release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and include, among other things, statements regarding the development, clinical evaluation, regulatory review and approval, commercialization and market adoption of MicroPort products and technologies; anticipated clinical, operational or commercial benefits; market opportunities; business and geographic expansion; and MicroPort's strategies, plans, objectives, expectations, projections and estimates. Such statements may be identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "plans," "projects," "may," "will," "could," and similar expressions.
Forward-looking statements are based on current expectations, assumptions and information available as of the date of this press release and are subject to known and unknown risks and uncertainties, many of which may be difficult to predict or beyond MicroPort's control. These may include, among others: the outcomes and timing of research and development activities, clinical studies and regulatory processes, including submissions, reviews, decisions and the obtaining, maintenance, expansion or renewal of approvals, clearances and registrations, product safety, quality, recalls or manufacturing issues, product liability claims, changes in laws, regulations, healthcare, pricing and procurement policies (including centralized or volume-based procurement programs) or reimbursement environments, market acceptance, competition, pricing pressure, and commercial performance, supply-chain disruptions and dependence on suppliers, distributors, collaboration partners and other third parties, the ability to obtain, maintain and enforce intellectual property rights, as well as intellectual property matters, disputes or litigation, cybersecurity, information security and data protection risks, compliance with applicable anti-corruption, export control, sanctions and healthcare industry laws and regulations, access to financing, currency fluctuations, tariffs, trade restrictions and other international trade measures, and general economic, industry, market or geopolitical conditions.
For additional information regarding risks and uncertainties, readers should refer to the annual and interim reports and other public disclosures of MicroPort Scientific Corporation and, where applicable, any listed subsidiary whose securities are publicly traded.
Actual results may differ materially from those expressed or implied in any forward-looking statement. There can be no assurance that products or technologies under development will successfully complete clinical evaluation, obtain or maintain regulatory approvals, clearances or registrations in any particular jurisdiction, be commercialized within anticipated timelines or at all, or achieve anticipated clinical or commercial outcomes.
Forward-looking statements speak only as of the date of this press release and are based on the assumptions and information available as of such date. In light of the risks, uncertainties and assumptions described above, readers are cautioned not to place undue reliance on such statements. Except as required by the SFO, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, or any other applicable law or regulation, MicroPort undertakes no obligation to publicly update or revise any forward-looking statement to reflect new information, future events or otherwise.

About Us
Healthcare Professionals
Patients
Reshaping Health
Investor Relations
Legal statement
Careers
©Copyright 2026, MicroPort Scientific Corporation. All rights reserved.
Shanghai ICP Filing No. 2023023560
| Public Security Filing No. 31011502014876
“MicroPort” and the “
” logo are registered trademarks of MicroPort Scientific Corporation and its affiliates.
×
Modal body text goes here.
Close